Drug Trial Radar · NCT06048887
Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Dec 18, 2020
Primary completion
Apr 11, 2022
Study completion Apr 11, 2022
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1, first-in-human, double-blind, randomized, placebo-controlled study to evaluate the safety of CRN04894 in healthy volunteers as well as the relationship between exposure and pharmacodynamic (PD) parameters.
Conditions
- Healthy Volunteers
Interventions
CRN04894 Oral SolutionDrug
CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
Placebo Oral SolutionDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with treatment-emergent adverse eventsTime frame: Part 1 - up to Day 8; Part 2 - up to Day 20
- Proportion of participants with a clinically significant safety laboratory observationTime frame: Part 1 - up to Day 8; Part 2 - up to Day 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
QPS-Miami Research Associates
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.